Abiopharma

🔍 Eisel Catherine (Executive)

Company: LINKBANCORP, Inc. (LNKB)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 23,643 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 7,800 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 7,066 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,000 shares of Stock Options at $6.58 per share (Derivative)
  Date: 2026-05-01 | Code: D | Expires: 2035-05-23 | Exercise: 2026-05-23 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Pursuant to the Agreement and Plan of Merger dated December 18, 2025 between the Issuer and Burke & Herbert Financial Services Corp. ("Burke & Herbert"), each issued and outstanding share of Issuer common stock was converted into the right to receive 0.1350 shares of common stock of Burke & Herbert. Holders of Issuer Common Stock will receive cash in lieu of fractional shares of Burke & Herbert common stock in accordance with the terms of the Agreement and Plan of Merger.
• F2: This option converted into a stock option exercisable for a number of shares of Burke & Herbert common stock equal to the number of shares of Issuer common stock underlying the option multiplied by 0.1350, rounded down to the nearest whole share, with an exercise price per share of Burke & Herbert common stock equal to the exercise price applicable to the underlying option divided by 0.1350, rounded up to the nearest cent.